Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:VEC
CUSIPN/A
Phone+44-1249-667700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-48.35%
Return on Equity-11.44%
Return on Assets-9.24%
Miscellaneous
EmployeesN/A
Outstanding Shares679,350,000
Market Cap£528.41 million
Vectura Group (LON:VEC) Frequently Asked Questions
What is Vectura Group's stock symbol?
Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC."
What price target have analysts set for VEC?
9 analysts have issued twelve-month price objectives for Vectura Group's shares. Their predictions range from GBX 78 to GBX 160. On average, they expect Vectura Group's share price to reach GBX 128.11 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price. View Analyst Price Targets for Vectura Group.
What is the consensus analysts' recommendation for Vectura Group?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vectura Group in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vectura Group.
Who are some of Vectura Group's key competitors?
Some companies that are related to Vectura Group include Mayne Pharma Group (MYX), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Sinclair Pharma (SPH), Pharmaxis (PXS), NanoViricides (NNVC), Futura Medical (FUM), Cathay International (CTI), Sareum (SAR), N4 Pharma (N4P), China Pharma (CPHI), Avivagen (VIV) and Bayer (BAYN).
Who are Vectura Group's key executives?
Vectura Group's management team includes the folowing people:
- Mr. James Ward-Lilley, CEO & Exec. Director (Age 53)
- Mr. Anthony Fitzpatrick, Exec. VP of Operations
- Elizabeth Knowles, Director of Investor Relations & Analysis
- Mr. John Murphy, Gen. Counsel & Company Sec. (Age 65)
- Fleur Wood, Director of Communications
Has Vectura Group been receiving favorable news coverage?
News coverage about VEC stock has trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vectura Group earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Vectura Group.
How do I buy shares of Vectura Group?
Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Vectura Group's stock price today?
One share of VEC stock can currently be purchased for approximately GBX 77.60.
How big of a company is Vectura Group?
Vectura Group has a market capitalization of £528.41 million.
How can I contact Vectura Group?
Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700.
MarketBeat Community Rating for Vectura Group (LON VEC)
MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote "Outperform" if you believe VEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
